{"id":"premarin-vaginal-estrogen-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaginal irritation or discharge"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain or bloating"}]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The cream contains conjugated estrogens (a mixture of estrone and equilin sulfates derived from pregnant mare urine) that are absorbed through the vaginal epithelium. These estrogens bind to estrogen receptors in vaginal and urethral tissues, restoring tissue elasticity, moisture, and blood flow. This reverses the atrophic changes caused by estrogen deficiency in menopause.","oneSentence":"Premarin vaginal cream delivers conjugated estrogens directly to vaginal tissue to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:22.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vaginal atrophy and urogenital symptoms associated with menopause"},{"name":"Atrophic vaginitis"}]},"trialDetails":[{"nctId":"NCT07030426","phase":"PHASE3","title":"Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-10-01","conditions":"Pelvic Organ Prolapse (POP)","enrollment":180},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT01648751","phase":"NA","title":"Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse","status":"TERMINATED","sponsor":"Pamela Moalli","startDate":"2012-05","conditions":"Pelvic Organ Prolapse","enrollment":21},{"nctId":"NCT03996603","phase":"PHASE4","title":"Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-08-01","conditions":"Female Urogenital Diseases, Vaginal Atrophy, Postmenopausal Atrophic Vaginitis","enrollment":25},{"nctId":"NCT04301934","phase":"NA","title":"Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-06-01","conditions":"Urinary Tract Infections","enrollment":12},{"nctId":"NCT02431897","phase":"PHASE4","title":"Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-12","conditions":"Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse","enrollment":206},{"nctId":"NCT05118685","phase":"PHASE1","title":"Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2021-11-13","conditions":"Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis","enrollment":100},{"nctId":"NCT05464654","phase":"NA","title":"Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause","status":"COMPLETED","sponsor":"Hospital Regional 1o de Octubre","startDate":"2021-06-23","conditions":"Genitourinary Syndrome of Menopause, Postmenopausal Disorder, Menopause","enrollment":136},{"nctId":"NCT02213757","phase":"PHASE4","title":"Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2014-08","conditions":"Microscopic Hematuria","enrollment":29},{"nctId":"NCT03943823","phase":"PHASE4","title":"Postmenopausal Pessary Users: Estrogen Versus Trimosan","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-05-07","conditions":"Vaginosis, Vaginosis, Bacterial, Vaginal Discharge","enrollment":4},{"nctId":"NCT04606550","phase":"NA","title":"MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study","status":"WITHDRAWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2021-09-01","conditions":"Breast Cancer Female, Genitourinary Syndrome of Menopause","enrollment":""},{"nctId":"NCT02835846","phase":"PHASE4","title":"Investigation of the Effect of the Female Urinary Microbiome on Incontinence","status":"COMPLETED","sponsor":"Loyola University","startDate":"2016-09","conditions":"Overactive Bladder, Incontinence, Nocturia","enrollment":35},{"nctId":"NCT02869165","phase":"PHASE4","title":"Vaginal and Urinary Microbiome Trial","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2017-01","conditions":"Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections","enrollment":110},{"nctId":"NCT02524769","phase":"NA","title":"The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides","status":"COMPLETED","sponsor":"Loyola University","startDate":"2015-12","conditions":"Overactive Bladder","enrollment":27},{"nctId":"NCT01958073","phase":"PHASE4","title":"Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-10","conditions":"Recurrent Urinary Tract Infection","enrollment":35},{"nctId":"NCT04393194","phase":"PHASE4","title":"The Effect of Intra-vaginal Conjugated Estrogen Cream on Ring Pessary Use for Pelvic Organ Prolapse","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-05-24","conditions":"Pelvic Floor Prolapse","enrollment":420},{"nctId":"NCT02691936","phase":"NA","title":"Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-03","conditions":"Atrophic Vaginitis, Menopause","enrollment":69},{"nctId":"NCT03266926","phase":"","title":"Does the Use of Bupivacaine Soaked Vaginal Packing Following Vaginal Surgery Decrease Postoperative Pain?","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2017-02-01","conditions":"Pelvic Organ Prolapse, Postoperative Pain","enrollment":140},{"nctId":"NCT03032848","phase":"PHASE4","title":"Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients","status":"COMPLETED","sponsor":"Universidade Federal do Paraná","startDate":"2013-11-26","conditions":"Vaginitis Atropic, Pelvic Organ Prolapse, Endometrial Hyperplasia","enrollment":69},{"nctId":"NCT01843166","phase":"NA","title":"Vaginal Estrogen With Pessary Treatment","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Vaginal Infection, Urinary Tract Infection, Quality of Life","enrollment":150},{"nctId":"NCT02860897","phase":"PHASE4","title":"Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-07","conditions":"Estrogen, Menopause, Pelvic Floor Disorders","enrollment":""},{"nctId":"NCT03018106","phase":"PHASE4","title":"Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-06-30","conditions":"Sexual Dysfunction, Physiological","enrollment":1},{"nctId":"NCT01613170","phase":"PHASE4","title":"Premarin Versus Toviaz for Treatment of Overactive Bladder","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2012-04","conditions":"Overactive Bladder","enrollment":90},{"nctId":"NCT00803335","phase":"PHASE3","title":"The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse","status":"COMPLETED","sponsor":"TriHealth Inc.","startDate":"2008-12","conditions":"Pelvic Organ Prolapse, Vaginal Atrophy","enrollment":54},{"nctId":"NCT00361569","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2006-08","conditions":"Menopause","enrollment":622},{"nctId":"NCT01778985","phase":"PHASE4","title":"Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-12","conditions":"Pelvic Organ Prolapse, Menopause","enrollment":30},{"nctId":"NCT00484107","phase":"","title":"Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-09","conditions":"Postmenopause","enrollment":200},{"nctId":"NCT00167921","phase":"PHASE1","title":"Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Atrophic Vaginitis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Conjugated estrogens vaginal cream"],"phase":"marketed","status":"active","brandName":"Premarin vaginal estrogen cream","genericName":"Premarin vaginal estrogen cream","companyName":"Medstar Health Research Institute","companyId":"medstar-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Premarin vaginal cream delivers conjugated estrogens directly to vaginal tissue to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital symptoms. Used for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}